03.05.26 -- Thoughtful Supply Strategy Is No Longer Optional In Drug Development

Stepwise engineering produces ABEs with tunable potency, precision, PAM range, and context specificity, enabling robust and targeted genome editing across diverse therapeutic sites.

Policy, trade, and security pressures are fundamentally reshaping global biologics manufacturing. Forward-looking companies are onshoring critical programs to mitigate risks to supply chains.

GLP‑1 therapies are changing injectable care and driving rapid progress in delivery and manufacturing. See how patient needs, emerging tech, and regulations are reshaping chronic treatment.

In our series on pre-filled syringes, we explore five key ways this delivery format is enhancing patient outcomes, not just through the medicine it contains, but through the device design itself.

Experience the benefits of faster, more effective CAR-T cell production with this innovative three-day short-cycle process, designed to enhance patient treatment outcomes while reducing costs.

Establishing unified component standards through collaborative innovation eliminates unnecessary investment, reduces development timelines, and ensures scalable, patient-centered delivery systems.

To ensure the success of gene therapy, learn why it is crucial to partner with a CRO that can navigate the challenges of viral vector development and testing.

Review the development of a high-strength synthetic gene promoter that enhances titers while maintaining exceptional product quality, to support more efficient biomanufacturing.